Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Antril, ready or not

Antril, ready or not

Fasten your seat belts and step onto the Synergen Inc. roller-coaster. The consensus among the biotech watchers has long been that the company's presentation of its Phase III Antril data will be the event of the year for the group. And, like it or

Read the full 484 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers